Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8301581 | 1.00 | CXCR4 (0.41) | CXCR4MEN1KMT2AOPRL1ADRB2 | |
| SCHEMBL8306821 | 0.93 | CXCR4 (0.45) | CXCR4MEN1KMT2AOPRL1OPRM1 | |
| SCHEMBL8305930 | 0.91 | PRMT6 (0.42) | CXCR4OPRL1CYP2D6CYP3A4NCF1 | |
| SCHEMBL2470097 | 0.91 | PRMT6 (0.42) | CXCR4OPRL1CYP2D6CYP3A4NCF1 | |
| SCHEMBL11983265 | 0.87 | CXCR4 (0.41) | CXCR4MEN1KMT2AOPRL1OPRM1 | |
| SCHEMBL2472770 | 0.87 | CXCR4 (0.43) | CXCR4MEN1KMT2AOPRL1OPRM1 | |
| SCHEMBL2474583 | 0.84 | CXCR4 (0.44) | CXCR4MEN1KMT2A | |
| SCHEMBL2472736 | 0.84 | CXCR4 (0.41) | CXCR4OPRL1CYP2D6CYP3A4OPRM1 | |
| SCHEMBL8304668 | 0.84 | CXCR4 (0.41) | CXCR4OPRL1CYP2D6CYP3A4OPRM1 | |
| SCHEMBL2470469 | 0.83 | CXCR4 (0.38) | CXCR4MEN1KMT2AOPRL1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615633-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2012-08-15 | — | — | EP | claimed |
| EP-2374804-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | Genzyme Corporation (US) | 2011-10-12 | — | — | EP | claimed |
| EP-2664617-A1 | Method of making a 2,6-diaryl piperidine derivative | Genzyme Corporation (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-1615633-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2374804-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | Genzyme Corporation (US) | 2011-10-12 | — | — | EP | disclosed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7501518-B2 | Methods of making 2,6-diaryl piperidine derivatives | GENZYME CORPORATION (US) | 2009-03-10 | — | — | US | disclosed |
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ANORMED CORPORATION (CA) | 2005-07-14 | — | — | US | disclosed |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ALDH7A1, DPYD, ALDH1A1 | CXCR4 2190/4885MEN1 2676/4885KMT2A 1667/4885 |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CXCR4, CXCR1, CCR5 | CXCR4 1/4885MEN1 4295/4885KMT2A 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.